



23 December 2020

And We're Racing – Trikafta is on the PBAC March Agenda

Today we had confirmation that Trikafta, the cystic fibrosis wonder drug, is on the Pharmaceutical Benefits Advisory Committee (PBAC) March 2021 Agenda and there will be a decision about access to this drug for 90% of people with CF over the age of 12 years on 23 April 2021.

Trikafta Facts:

1. This the 3rd generation CF multi-drug, greatly improves the positive effects of existing CFTR modulators
2. Has the potential to give 90% of Australian with CF, decades of life
3. Reduces lung damage, exacerbations, hospitalisations and antibiotic use
4. Increases BMI and staves off CF Related Diabetes and CF Related Liver Disease
5. Improves the mental health of patients and the family unit by reducing stress, anxiety and depression
6. Allows people with CF to lead a fulfilling life that includes education, employment, starting a family and the development of social networks
7. Reduces the burden of the disease both physically and financially
8. Is available to patients in England, Ireland, USA, Denmark and Germany and now it is Australia's time.

Trikafta is a one of a kind CF drug that combines elexacaftor, tezacaftor and ivacaftor into a treatment of unprecedented efficiency and impact. The clinical trial data is outstanding, and CFA believes that when put through the rigorous PBAC process Trikafta will stand out as a winner. Even so, this does not mean people with CF get access.

CFA is warning our health regulators and Vertex not to confuse what a life is worth with what a life costs.

CFA is appealing to Vertex Pharmaceuticals to provide all eligible people with Compassionate Access immediately following a PBAC positive recommendation.

Over the next five years it is estimated that Trikafta will generate US\$6.6 billion for Vertex. CFA believes this is outstanding shareholder value and a few months' free supply of Trikafta for 1200 Australians is reasonable. It may even speed up commercial negotiations.

It's time to activate and time to tell your story and inspiring others to do the same. There is nothing as compelling as a 'real life experience' story so contact nickim@cfa.org.au at CFA to provide a case study.

Here are some important links that will assist you in your Trikafta Access advocacy. CFA Trikafta Advocacy Portal [HERE](#). PBAC Consumer Comments Portal [HERE](#). The portal closes on 27 January 2021 so don't delay and get in now to have your say.

Kind regards

A handwritten signature in black ink, appearing to read "Nettie Burke". The signature is fluid and cursive, with the first name "Nettie" being more prominent than the last name "Burke".

Nettie Burke, CEO
Cystic Fibrosis Australia
0404 034 294
nettieb@cfa.org.au